IRB Amendment

Att 5a_ Amendment IRB Approval 1 Protocol #7224 (002).pdf

Using Qualitative Methods to Understand Issues in HIV Prevention, Care and Treatment in the United States

IRB Amendment

OMB: 0920-1091

Document [pdf]
Download: pdf | pdf
Public Health Service
DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Disease Control
and Prevention (CDC)

Memorandum
Date
d
From

September 25, 2020

Subject

IRB Approval of CDC Protocol #7224.0, Amendment #1, "Quantitative research to understand
consumer opinions and preferences for emerging HIV prevention products among MSM in
Atlanta" (Expedited)

To

Ayana Stanley, DrPH
NCHHSTP/DHAP

LaShonda Roberson, DHSc, MPH
CDR, USPHS
Sr. IRB Administrator
Human Research Protection Office

CDC IRB Committee 1 has reviewed and approved your request to amend protocol 7224.0,
“Quantitative research to understand consumer opinions and preferences for emerging HIV
prevention products among MSM in Atlanta”. The modification includes the following changes:
We are recommending an expansion of sites for the 2PM study, from Atlanta solely to three
separate sites including Atlanta. This would reduce the burden on Atlanta where there is research
fatigue in the population and competition for research subjects. As Atlanta has a considerably
large MSM population, there are also many research projects that also seek to recruit, enroll, and
retain this group in studies. At Emory University, for example, there are thousands of MSM
enrolled in the 20 PRISM (Programs, Research, Innovation in Sexual Minority Health) studies.
Additionally, there are other active investigators throughout the Atlanta metropolitan area who
are recruiting the same populations for their studies at Emory University, Georgia State
University, the University of Georgia, Mercer University, GA Tech, as well as research teams at
other universities, colleges, community-based and AIDS-service organizations, government and
non-governmental agencies. Currently, there are 7 active and planned clinical trial investigations
listed on clinicaltrials.gov, including those examining biomedical prevention options, including
those being conducted as multisite studies (e.g.,
https://clinicaltrials.gov/ct2/show/NCT03729570?term=gaymen&recrs=ab&map_cntry=US&ma
p_state=US%3AGA&draw=2&rank=4).
We would like to add two new jurisdictions: Houston, TX and Miami, FL, both cities are part of
Ending of the Epidemic. (p 15 & 16 of protocol)
Due to the study being conducted virtually, audio recording of verbal consent will be requested
prior to conducting the short survey and the IDI or FG (p. 21 & 30 in protocol, Appendix B)
Conduct virtual data collection instead of in-person due to the COVID-19 pandemic. (p 25 in
protocol)

Public Health Service
DEPARTMENT OF HEALTH & HUMAN SERVICES

Centers for Disease Control
and Prevention (CDC)

The action was reviewed in accordance with the expedited review process outlined in 45 CFR
46.110(b)(2) category 7, minor changes to previously approved research during the period of one
year for which approval is authorized.
Reminder: IRB approval of protocol #7224.0 will still expire on 12/21/2030.
Any problems of a serious nature must be brought to the immediate attention of the CDC
IRB, and any proposed changes to the protocol should be submitted as an amendment to
the protocol for CDC IRB approval before they are implemented.
If you have any questions, please contact your National Center Human Subjects Contact or the
CDC Human Research Protection Office (404) 639-7570 or e-mail: [email protected].
cc:
NCHHSTP Human Subjects Review (CDC)


File Typeapplication/pdf
File Modified2020-11-12
File Created2020-11-12

© 2024 OMB.report | Privacy Policy